Terumo (OTCMKTS:TRUMY) Sets New 12-Month Low – Here’s Why

Terumo Corp. (OTCMKTS:TRUMY)’s share price hit a new 52-week low during trading on Tuesday . The company traded as low as $13.01 and last traded at $13.46, with a volume of 2708 shares traded. The stock had previously closed at $13.72.

Terumo Trading Down 1.6%

The company has a quick ratio of 1.46, a current ratio of 2.51 and a debt-to-equity ratio of 0.07. The company’s fifty day moving average price is $14.72 and its two-hundred day moving average price is $16.23. The firm has a market cap of $19.91 billion, a PE ratio of 22.49 and a beta of 0.75.

Terumo (OTCMKTS:TRUMY) last posted its quarterly earnings results on Wednesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Terumo had a net margin of 12.35% and a return on equity of 9.39%. The firm had revenue of $1.86 billion during the quarter, compared to analysts’ expectations of $1.75 billion.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.